Solventum Corporation SOLV is well-poised for growth in the coming quarters, driven by strong demand across its business segments, supported by continued investment in innovation, R&D and digital capabilities. The optimism, led by a solid first-quarter 2026 performance and a solid restructuring program, is expected to contribute further. However, concerns regarding the rise in raw material costs persist.
In the year-to-date period, this Zacks Rank #3 (Hold) company’s shares have lost 2.5% compared with the industry’s 3.2% decline. The S&P 500 increased 9.3% in the same time frame.
The renowned global healthcare solutions provider has a market capitalization of $13.45 billion. The company projects 7.7% earnings growth for 2026 and expects to maintain its strong performance going forward. Solventum’s earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 8.9%.
Let’s delve deeper.
Image Source: Zacks Investment Research
Key Drivers of SOLV Stock
Future Cost Transformation Program: Solventum continues to execute its Transform for the Future program, which targets approximately $500 million in annual cost savings through operational efficiencies, automation and system simplification, with most benefits expected from 2027 onward. For 2026, management still expects 50-100 basis points of operating margin expansion, supported by sales leverage, cost-saving initiatives and portfolio optimization despite higher tariff costs.
The company is also making steady progress on its separation activities, having exited more than half of its transition service agreements and expecting to surpass 90% by year-end 2026. The planned completion of its final major ERP migration in the United States and Canada during the third quarter should further reduce operational complexity and support long-term efficiency gains.
Strategic Growth Drivers: Solventum’s long-term growth strategy remains centered on five priority growth drivers expected to generate more than 80% of future growth. Within MedSurg, negative pressure wound therapy continues to gain traction through strong demand for traditional and single-use systems, broader adoption of the V.A.C. Peel and Place Dressing and the recent Acera Surgical acquisition, which strengthens the company’s position in the synthetic tissue matrix market.
IV site management is benefiting from robust uptake of Tegaderm CHG, while Sterilization Assurance continues to see healthy demand supported by the Attest product portfolio and stronger commercial execution. The company also plans to launch nearly 20 new products over the next two years, reinforcing its innovation-led growth strategy.
In Dental Solutions, core restoratives remain a key growth driver, supported by strong demand for Filtek Easy Match, Clinpro Clear and the Clarity Aligner portfolio, along with improved supply chain execution and customer engagement. Meanwhile, Health Information Systems continues to benefit from growing adoption of the 360 Encompass platform, international expansion and rising demand for AI-enabled autonomous coding solutions. Backed by proprietary reimbursement data, coding expertise and specialized commercial capabilities, Solventum is well positioned to capitalize on the increasing use of AI in healthcare revenue cycle management.
Solid Q1 Results: Solventum exited the first quarter of 2026 on a strong note, with both earnings and revenues surpassing the Zacks Consensus Estimate. The company continued to witness improving commercial momentum across all three segments, driven by volume growth, new product launches and operational execution.
Strength in MedSurg was led by negative pressure wound therapy, Tegaderm CHG and sterilization products, while Dental Solutions benefited from strong adoption of Filtek Easy Match and Clinpro Clear, supported by improved supply-chain execution and lower backorders. Health Information Systems also remained solid, aided by continued traction in revenue cycle management and autonomous coding solutions.
Downsides of SOLV Stock
Potential Raw Material Cost Step-Up From 3M Supply Agreement: Solventum disclosed that under its long-term supply agreement with 3M, the supplier holds a contractual option in 2027 to increase the cost of certain raw materials supplied. If this option is exercised, it could create a 100-basis-point margin headwind.
The company emphasized that it is actively working with 3M to explore alternatives that could avoid this outcome. SOLV owns the intellectual property rights for these materials within its field of use, meaning it has the option to source the materials from other chemical manufacturers if necessary.
Trend in Estimate Revision
SOLV has been witnessing a stable estimate revision trend for 2026. In the past 30 days, the Zacks Consensus Estimate for its earnings per share (EPS) has remained stable at $6.58.
The Zacks Consensus Estimate for the company’s second-quarter revenues is pegged at $2.17 billion, implying 0.2% growth from the year-ago quarter’s reported number.
Key Picks
Some better-ranked stocks from the broader medical space are West Pharmaceutical WST, Intuitive Surgical ISRG and Cardinal Health CAH, each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
West Pharmaceutical reported first-quarter 2026 earnings per share of $2.13, which beat the Zacks Consensus Estimate by 26.8%. Revenues of $844.9 million surpassed the Zacks Consensus Estimate by 8.5%.
West Pharmaceutical has an estimated long-term earnings growth rate of 13.9%. WST’s earnings surpassed estimates in the trailing four quarters, the average surprise being 19.4%.
Intuitive Surgical reported first-quarter 2026 adjusted EPS of $2.50, which beat the Zacks Consensus Estimate by 20.2%. Revenues of $2.77 billion surpassed the Zacks Consensus Estimate by 6.2%.
Intuitive Surgical has an estimated long-term earnings growth rate of 14.3%. ISRG’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%.
Cardinal Health reported a third-quarter fiscal 2026 adjusted EPS of $3.17, which beat the Zacks Consensus Estimate by 13.2%. Revenues of $60.94 billion missed the Zacks Consensus Estimate by 2.3%.
Cardinal Health has an estimated long-term earnings growth rate of 17%. CAH’s earnings surpassed estimates in the trailing four quarters, the average surprise being 10.3%.
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."
Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.9% per year. So be sure to give these hand picked 7 your immediate attention.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
(0) comments
Welcome to the discussion.
Log In
Keep it Clean. Please avoid obscene, vulgar, lewd, racist or sexually-oriented language.
PLEASE TURN OFF YOUR CAPS LOCK.
Don't Threaten. Threats of harming another person will not be tolerated.
Be Truthful. Don't knowingly lie about anyone or anything.
Be Nice. No racism, sexism or any sort of -ism that is degrading to another person.
Be Proactive. Use the 'Report' link on each comment to let us know of abusive posts.
Share with Us. We'd love to hear eyewitness accounts, the history behind an article.